- Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
- Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
- Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority
- Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer
- Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
- Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
- Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA
- Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19
- Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023
More ▼
Key statistics
On Wednesday, Shanghai Junshi Biosciences Co Ltd (688180:SHH) closed at 29.80, 24.17% above the 52 week low of 24.00 set on Feb 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 29.70 |
---|---|
High | 30.66 |
Low | 29.12 |
Bid | 29.80 |
Offer | 29.81 |
Previous close | 29.73 |
Average volume | 7.02m |
---|---|
Shares outstanding | 985.69m |
Free float | 584.70m |
P/E (TTM) | -- |
Market cap | 25.61bn CNY |
EPS (TTM) | -2.06 CNY |
Data delayed at least 15 minutes, as of Mar 13 2024 07:00 BST.
More ▼